

**PharmaCyte Biotech, Inc.**  
3960 Howard Hughes Parkway  
Suite 500  
Las Vegas, NV 89169

November 15, 2021

VIA EDGAR  
Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549-3720

Attention: Gary Guttenberg

Re: PharmaCyte Biotech, Inc.  
Registration Statement on Form S-3  
Filed November 8, 2021  
File No. 333-260849

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, PharmaCyte Biotech, Inc. (the "**Company**") hereby requests that the effective date of the Company's Registration Statement on Form S-3 (File No. 333-260849) (the "**Registration Statement**") be accelerated so that the Company's Registration Statement will become effective on **Wednesday, November 17, 2021 at 5:30 p.m.** (Eastern Time), or as soon thereafter as practicable.

Please feel free to direct any questions or comments concerning this request to Merrill M. Kraines, Esq. of Troutman Pepper Hamilton Sanders LLP at (212) 808-2711.

The Company understands that the staff of the United States Securities and Exchange Commission will consider this request as confirmation by the Company that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.

**PHARMACYTE BIOTECH, INC.**

By: /s/ Kenneth L. Waggoner  
Name: Kenneth L. Waggoner  
Title: Chief Executive Officer

cc: Merrill M. Kraines, Troutman Pepper Hamilton Sanders LLP